Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: 6 Henrietta Street
London
WC2E 8PU
Tel: +44 (0)20 7557 7500
Web: http://www.mvmlifescience.com/
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs).
The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.
Heptares Therapeutics Ltd deploys structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets. They develop small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
